293 related articles for article (PubMed ID: 35196427)
1. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
[TBL] [Abstract][Full Text] [Related]
2. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
3. New Means and Challenges in the Targeting of BTK.
Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
[TBL] [Abstract][Full Text] [Related]
4. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K; Puła B
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
[TBL] [Abstract][Full Text] [Related]
5. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
[TBL] [Abstract][Full Text] [Related]
6. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
8. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
10. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
[TBL] [Abstract][Full Text] [Related]
11. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract][Full Text] [Related]
12. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
15. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
16. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
[TBL] [Abstract][Full Text] [Related]
17. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S; Bourcier J; Noviski M; Lu H; Thompson MC; Chirino A; Jahn J; Sondhi AK; Gajewski S; Tan YSM; Yung S; Urban A; Wang E; Han C; Mi X; Kim WJ; Sievers Q; Auger P; Bousquet H; Brathaban N; Bravo B; Gessner M; Guiducci C; Iuliano JN; Kane T; Mukerji R; Reddy PJ; Powers J; Sanchez Garcia de Los Rios M; Ye J; Barrientos Risso C; Tsai D; Pardo G; Notti RQ; Pardo A; Affer M; Nawaratne V; Totiger TM; Pena-Velasquez C; Rhodes JM; Zelenetz AD; Alencar A; Roeker LE; Mehta S; Garippa R; Linley A; Soni RK; Skånland SS; Brown RJ; Mato AR; Hansen GM; Abdel-Wahab O; Taylor J
Science; 2024 Feb; 383(6682):eadi5798. PubMed ID: 38301010
[TBL] [Abstract][Full Text] [Related]
18. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
19. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
[TBL] [Abstract][Full Text] [Related]
20. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
